炎症性肠病患者的肠易激综合征症状——合并或不同实体的表现
IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities.
作者信息
Szałwińska Patrycja, Włodarczyk Jakub, Spinelli Antonino, Fichna Jakub, Włodarczyk Marcin
机构信息
Department of Biochemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Department of General and Colorectal Surgery, Medical University of Lodz, Haller Square 1, 90-624 Lodz, Poland.
出版信息
J Clin Med. 2020 Dec 24;10(1):31. doi: 10.3390/jcm10010031.
Abstract
Irritable bowel syndrome (IBS) is a functional heterogenous disease with a multifactorial pathogenesis. It is characterized by abdominal pain, discomfort, and alteration in gut motility. The occurrence of similar symptoms was observed in patients in clinical remission of inflammatory bowel diseases (IBD) that is Crohn's disease (CD) and ulcerative colitis (UC), which pathogenesis is also not fully understood. Hence, arose the question if these symptoms are "true IBS" imposed on IBD, or is it a subclinical form of IBD or even pre-IBD? In this article, based on a narrative overview of the literature, we try to find an answer to this query by discussing the pathogenesis and overlaps between these conditions.
摘要
肠易激综合征（IBS）是一种具有多因素发病机制的功能性异质性疾病。其特征为腹痛、不适以及肠道动力改变。在炎症性肠病（IBD）即克罗恩病（CD）和溃疡性结肠炎（UC）临床缓解期的患者中也观察到了类似症状，其发病机制同样尚未完全明确。因此，出现了这样一个问题：这些症状是叠加于IBD的“真正的IBS”，还是IBD的亚临床形式甚至是IBD前期表现？在本文中，基于对文献的叙述性综述，我们试图通过讨论这些病症之间的发病机制和重叠情况来找到这个问题的答案。
相似文献
1
IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities.炎症性肠病患者的肠易激综合征症状——合并或不同实体的表现
J Clin Med. 2020 Dec 24;10(1):31. doi: 10.3390/jcm10010031.
2
Predictors of irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease.缓解期炎症性肠病中肠易激综合征样症状的预测因素。
Neurogastroenterol Motil. 2024 Jun;36(6):e14809. doi: 10.1111/nmo.14809. Epub 2024 Apr 23.
3
Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.炎症性肠病患者出现真正的肠易激综合征样症状对心理健康和生活质量的负面影响。
Clin Gastroenterol Hepatol. 2017 Mar;15(3):376-384.e5. doi: 10.1016/j.cgh.2016.05.012. Epub 2016 May 14.
4
Comparison of geographic distributions of Irritable Bowel Syndrome with Inflammatory Bowel Disease fail to support common evolutionary roots: Irritable Bowel Syndrome and Inflammatory Bowel Diseases are not related by evolution.肠易激综合征和炎症性肠病的地理分布比较不能支持共同的进化根源：肠易激综合征和炎症性肠病在进化上没有关系。
Med Hypotheses. 2018 Jan;110:31-37. doi: 10.1016/j.mehy.2017.10.020. Epub 2017 Nov 2.
5
Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission.钙卫蛋白可作为鉴别缓解期炎症性肠病患者伴发的隐匿性炎症与肠易激样症状的有效工具。
Gastroenterol Res Pract. 2013;2013:620707. doi: 10.1155/2013/620707. Epub 2013 Feb 6.
6
The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.炎症性肠病缓解期患者中肠易激综合征型症状的患病率。
Eur J Gastroenterol Hepatol. 2017 Sep;29(9):1086-1090. doi: 10.1097/MEG.0000000000000921.
7
Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.静止期炎症性肠病中的功能性肠病症状：上皮屏障破坏和低水平炎症的作用。
Gut. 2014 May;63(5):744-52. doi: 10.1136/gutjnl-2012-304066. Epub 2013 Jul 22.
8
Diagnostic Implications of Irritable Bowel Syndrome Is an Independent Risk Factor for Undergoing Surgical Interventions in Patients with Inflammatory Bowel Disease.肠易激综合征的诊断意义是炎症性肠病患者接受手术干预的独立危险因素。
Diagnostics (Basel). 2023 May 29;13(11):1901. doi: 10.3390/diagnostics13111901.
9
[Emotional and personality features of patients with irritable bowel syndrome and bowel inflammatory diseases].[肠易激综合征和肠道炎症性疾病患者的情绪及人格特征]
Klin Med (Mosk). 2016;94(10):764-9.
10
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.粪便钙卫蛋白是炎症性肠病内镜下病变的替代标志物。
Inflamm Bowel Dis. 2012 Dec;18(12):2218-24. doi: 10.1002/ibd.22917. Epub 2012 Feb 16.
引用本文的文献
1
FastColitisDetector-XAI: An efficient AI model utilizing sparse Autoencoder with explainable AI for ulcerative colitis diagnosis.快速结肠炎检测器-XAI：一种利用稀疏自动编码器和可解释人工智能的高效人工智能模型用于溃疡性结肠炎诊断。
MethodsX. 2025 May 8;14:103356. doi: 10.1016/j.mex.2025.103356. eCollection 2025 Jun.
2
Crohn's disease, irritable bowel syndrome, and chronic fatigue: the importance of communication and symptom management-a case report.克罗恩病、肠易激综合征与慢性疲劳：沟通及症状管理的重要性——一例病例报告
J Med Case Rep. 2025 Jan 9;19(1):9. doi: 10.1186/s13256-024-05010-3.
3
Network pharmacology integrated with molecular docking and molecular dynamics simulations to explore the mechanism of Shaoyao Gancao Tang in the treatment of asthma and irritable bowel syndrome.网络药理学结合分子对接和分子动力学模拟以探究芍药甘草汤治疗哮喘和肠易激综合征的机制。
Medicine (Baltimore). 2024 Dec 13;103(50):e40929. doi: 10.1097/MD.0000000000040929.
4
Potential diagnostic markers and therapeutic targets for non-alcoholic fatty liver disease and ulcerative colitis based on bioinformatics analysis and machine learning.基于生物信息学分析和机器学习的非酒精性脂肪性肝病和溃疡性结肠炎的潜在诊断标志物及治疗靶点
Front Med (Lausanne). 2024 Nov 6;11:1323859. doi: 10.3389/fmed.2024.1323859. eCollection 2024.
5
Mechanisms of Action of Exclusive Enteral Nutrition and Other Nutritional Therapies in Crohn's Disease.克罗恩病中肠内营养及其他营养疗法的作用机制。
Nutrients. 2024 Oct 22;16(21):3581. doi: 10.3390/nu16213581.
6
miR-155 and miR-21 as Diagnostic and Therapeutic Biomarkers for Ulcerative Colitis: There Is Still a Long Way to Go.微小RNA-155和微小RNA-21作为溃疡性结肠炎的诊断和治疗生物标志物：仍有很长的路要走。
Biomedicines. 2024 Jun 13;12(6):1315. doi: 10.3390/biomedicines12061315.
7
Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey.欧洲炎症性肠病患者的残余疾病负担：一项真实世界调查
Inflamm Bowel Dis. 2025 Feb 6;31(2):411-424. doi: 10.1093/ibd/izae119.
8
Disease clearance in ulcerative colitis: A new therapeutic target for the future.溃疡性结肠炎的疾病清除：未来的一个新治疗靶点。
World J Gastroenterol. 2024 Apr 7;30(13):1801-1809. doi: 10.3748/wjg.v30.i13.1801.
9
Four-year follow-up of psychiatric and psychosomatic profile in patients with Inflammatory Bowel Disease (IBD).炎症性肠病（IBD）患者的精神和身心状况的四年随访。
BMC Psychol. 2024 Apr 17;12(1):211. doi: 10.1186/s40359-024-01726-5.
10
Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.钙卫蛋白、白细胞介素-6 和 C 反应蛋白在鉴别炎症性肠病与腹泻型肠易激综合征中的作用。
Med Arch. 2024;78(2):105-111. doi: 10.5455/medarh.2024.78.105-111.
本文引用的文献
1
Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.缓解期炎症性肠病患者肠易激综合征样症状的患病率：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1053-1062. doi: 10.1016/S2468-1253(20)30300-9. Epub 2020 Oct 2.
2
Role of Inflammation in Pathophysiology of Colonic Disease: An Update.炎症在结肠疾病发病机制中的作用：最新进展。
Int J Mol Sci. 2020 Jul 3;21(13):4748. doi: 10.3390/ijms21134748.
3
Human Intestinal Mononuclear Phagocytes in Health and Inflammatory Bowel Disease.人类肠道单核吞噬细胞在健康和炎症性肠病中的作用。
Front Immunol. 2020 Mar 18;11:410. doi: 10.3389/fimmu.2020.00410. eCollection 2020.
4
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.195 个国家和地区 1990-2017 年炎症性肠病的全球、区域和国家负担：2017 年全球疾病负担研究的系统分析。
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4. Epub 2019 Oct 21.
5
Does symptom activity explain psychological differences in patients with irritable bowel syndrome and inflammatory bowel disease? Results from a multi-center cross-sectional study.症状活动是否可以解释肠易激综合征和炎症性肠病患者的心理差异？一项多中心横断面研究的结果。
J Psychosom Res. 2019 Nov;126:109836. doi: 10.1016/j.jpsychores.2019.109836. Epub 2019 Sep 13.
6
Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.随机试验中低 FODMAP 饮食对处于缓解期炎症性肠病患者症状、粪便微生物群和炎症标志物的影响。
Gastroenterology. 2020 Jan;158(1):176-188.e7. doi: 10.1053/j.gastro.2019.09.024. Epub 2019 Oct 2.
7
Macrophage-Specific NF-κB Activation Dynamics Can Segregate Inflammatory Bowel Disease Patients.巨噬细胞特异性 NF-κB 激活动力学可将炎症性肠病患者分类。
Front Immunol. 2019 Sep 11;10:2168. doi: 10.3389/fimmu.2019.02168. eCollection 2019.
8
IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption.IFN-γ 通过 VE-cadherin 介导的血管屏障破坏驱动炎症性肠病发病机制。
J Clin Invest. 2019 Nov 1;129(11):4691-4707. doi: 10.1172/JCI124884.
9
Post-infectious Irritable Bowel Syndrome: A Narrative Review.感染后肠易激综合征：一篇叙述性综述。
Middle East J Dig Dis. 2019 Apr;11(2):69-75. doi: 10.15171/mejdd.2019.130. Epub 2019 Mar 25.
10
The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy.微生物群与肠易激综合征——病理生理学、当前研究及未来治疗的综述
Front Microbiol. 2019 Jun 10;10:1136. doi: 10.3389/fmicb.2019.01136. eCollection 2019.
Zotero 插件